2025-05-05 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**0. Key Figures Summary:**

* **Cumulative Return (MRK):** 22.90%
* **Cumulative Return (VOO):** 82.57%
* **Return Difference (MRK vs VOO):** -59.7%
* **Relative Divergence:** 19.3% (Indicates MRK's underperformance relative to VOO, but within the historical range of divergence.)
* **Current Price:** $79.84 (Closing price; Last market price shows a slight dip.)
* **5-day moving average:** $78.68
* **20-day moving average:** $81.72
* **60-day moving average:** $87.80
* **RSI:** 35.91 (Suggests the stock is possibly oversold)
* **PPO:** 0.12 (Positive, suggesting a potential bullish signal, but weak)
* **Market Risk Indicator (MRI):** 0.4053 (Medium risk)
* **Expected Return (Long-Term):** -16.6% (relative to S&P 500)


**1. Company Overview and Performance Comparison:**

Merck & Co Inc is a leading global healthcare company.  The provided data shows that MRK significantly underperformed the S&P 500 (VOO) over the analyzed period, with a cumulative return considerably lower than the benchmark.  The -59.7% difference represents a substantial underperformance.  The relative divergence of 19.3% places the current underperformance within the historical range of divergence but nearer the lower end indicating a period of consistent underperformance against the S&P 500.


**2. Recent Price Movement:**

The closing price of MRK is $79.84, slightly below the last market price of $83.18.  The stock is trading below its 5-day, 20-day, and 60-day moving averages, indicating a bearish short-term trend. The recent price action shows a relatively steady downtrend.

**3. Technical Indicators and Divergence:**

The RSI of 35.91 suggests the stock may be oversold, potentially indicating a bounce is due. However, this should be interpreted cautiously. The PPO of 0.12 is positive but weak, aligning with the generally bearish trend. The recent negative relative divergence of -4.9% reinforces the short-term bearish trend.  The negative expected return of -16.6% over the long term (2+ years) relative to the S&P 500 is a significant concern for investors. The MRI indicates a medium risk level.


**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue       |
|------------|-------|---------------|
| 2025-05-02 | 2.01  | $15.53 B      |
| 2024-11-06 | 1.25  | $16.66 B      |
| 2024-08-05 | 2.15  | $16.11 B      |
| 2024-05-03 | 1.88  | $15.78 B      |
| 2025-05-02 | 1.88  | $15.78 B      |


Earnings show some volatility. Revenue remains relatively consistent, while EPS fluctuates.  The duplication of the 2025-05-02 entry needs clarification (potential data entry error). A deeper dive into the factors driving these fluctuations is necessary for a complete assessment.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue      | Profit Margin |
|------------|--------------|---------------|
| 2025-03-31 | $15.53 B     | 77.98%        |
| 2024-12-31 | $15.62 B     | 75.50%        |
| 2024-09-30 | $16.66 B     | 75.51%        |
| 2024-06-30 | $16.11 B     | 76.76%        |
| 2024-03-31 | $15.78 B     | 77.56%        |

**Capital and Profitability:**

| Quarter    | Equity       | ROE           |
|------------|--------------|---------------|
| 2025-03-31 | $48.34 B     | 10.51%        |
| 2024-12-31 | $46.31 B     | 8.08%         |
| 2024-09-30 | $44.50 B     | 7.09%         |
| 2024-06-30 | $43.58 B     | 12.52%        |
| 2024-03-31 | $40.36 B     | 11.80%        |


Both revenue and profitability metrics show relatively stable performance, although there's some quarter-to-quarter variation. Equity has grown steadily, while ROE fluctuates.  Further analysis is needed to understand the drivers of these fluctuations and their impact on future performance.


**6. Overall Analysis:**

MRK's performance significantly lags the S&P 500, a concerning trend reflected in the negative expected return. While some indicators like RSI suggest potential oversold conditions, the overall picture is bearish, driven by the consistent underperformance against the benchmark, negative price action, and weak technical indicators.  The financial information displays relative stability, but further investigation into the drivers of earnings and ROE fluctuations is crucial.  Before considering investment, thorough due diligence is essential, focusing on the reasons for MRK's underperformance and the potential for future improvement. The projected long-term underperformance relative to the S&P 500 casts considerable doubt on the attractiveness of the stock at this time.
